Altimmune weight loss drug minimized muscle mass loss in trial

Altimmune on Wednesday said its experimental drug helped patients shed weight but also minimized the loss of muscle mass in a midstage trial, a finding that could set it apart in a potentially crowded market. Altimmune is one of several smaller biotech companies that are pushing to compete directly with Novo Nordisk and Eli Lilly … Read more

Wegovy heart health approval won’t mean broad insurance coverage yet

Victoria Klesty | Reuters In the U.S., Wegovy is no longer just for weight loss. The blockbuster drug — one of a handful of weight loss treatments to skyrocket in popularity over the last year — is now approved in the U.S. for heart health, too. But that may not translate to wider insurance coverage of … Read more

Wegovy heart health approval won’t mean broad insurance coverage yet

Victoria Klesty | Reuters In the U.S., Wegovy is no longer just for weight loss. The blockbuster drug — one of a handful of weight loss treatments to skyrocket in popularity over the last year — is now approved in the U.S. for heart health, too. But that may not translate to wider insurance coverage of … Read more

Weight-loss drugs like Wegovy are meant for long-term use. Some patients want to stop

Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like Wegovy are facing a new dilemma: What happens if they stop taking them? Many worry, rightly, that they’ll regain weight and revert to old habits. In clinical trials, patients who paused the drugs put back on most of the … Read more

The big decisions you’ll need to make once on new weight loss drugs

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.  Brendan Mcdermid | Reuters For all of the promise associated with new weight loss drugs such as Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound in treating obesity, there’s a very big risk printed right on … Read more

New pet drugs are looking a lot more like human medications

If you want to understand how different the human and animal medicine and vaccine industries have historically been, you don’t need to look much further than weight loss drugs. On the human side, Novo Nordisk and Eli Lilly struggled to meet the demand for Ozempic, Wegovy, Mounjaro and Zepbound, respectively, since introducing them, as the … Read more

What you need to know about health coverage for new weight loss drugs

Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss. Despite the hefty price tag — typically between $1,000 to $1,500 a month — consumers are clamoring for drugs like Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound. This class of drugs, historically used to … Read more

Novo Nordisk, Eli Lilly are tackling supply issues

Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters The insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments.  The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly, have said … Read more

Weight loss, diabetes drugs propel Eli Lilly to better-than-expected forecast for 2024

The popular diabetes treatment Mounjaro pushed Eli Lilly past fourth-quarter forecasts, and the drugmaker expects 2024 to turn out largely better than expected too, as new products build momentum. Lilly debuted on Tuesday a forecast for the new year that calls for adjusted earnings ranging from $12.20 to $12.70 per share as its new weight-loss … Read more

Bumper profits for Norway’s giant wealth fund led by a strong performance by tech companies

STAVANGER — Norway’s oil fund reported the largest annual return in its history Tuesday, a performance led by U.S. technology companies and Danish pharmaceutical company Novo Nordisk, which makes the diabetes-turned-weight loss drug Ozempic. Norway’s Government Pension Fund Global, the world’s largest sovereign wealth fund, said it also benefited in 2023 from market excitement over … Read more